Ketan K. Badani, MD, discusses the evolution of robotic retroperitoneal partial nephrectomies in renal cell carcinoma.
Ketan K. Badani, MD
Advertisement
Articles by Ketan K. Badani, MD
Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).
Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.
Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses the adoption of robotic surgery in kidney cancer.
Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the future of robotic surgery for patients with kidney cancer.
Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.
Advertisement
Latest Updated Articles
Dr. Badani on Utilizing Multiport Robotic Retroperitoneal Partial Nephrectomies in RCCPublished: September 10th 2021 | Updated:
Dr. Badani on the Benefits of Robotic Surgery for Kidney CancerPublished: May 25th 2017 | Updated:
Dr. Badani on the Future of Robotic Surgery for Kidney CancerPublished: June 6th 2017 | Updated:
Dr. Badani Discusses the Adoption of Robotic Kidney SurgeryPublished: August 21st 2017 | Updated:
Dr. Badani on Determining Which Patients With RCC Will Receive Robotic SurgeryPublished: September 6th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
5